Literature DB >> 33691674

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.

Annalisa Zeppellini1, Stefania Galimberti2, Biagio Eugenio Leone3,4, Claudia Pacifico5, Francesca Riva1, Federica Cicchiello1, Serena Capici6, Claudia Maggioni1, Luca Sala1, Marina Elena Cazzaniga3,6.   

Abstract

BACKGROUND: Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients.
METHODS: We retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9 years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%.
RESULTS: Our results showed that the microenvironment composition of relapsed patients was poor of TILs (median = 5%, I-III quartiles = 0.6-5%), CD8+ (2.5%, 0-5%) and CD4+/FOXP3 + (0%, 0-0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6-5%; CD8+ 0%, 0-1.3%; CD4+/FOXP3+ 0%,0-1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5-17.5%) in comparison to cases, both in primary tumor (p = 0.035) and related metastases (p = 0.018). Although CD8+ in controls were similar to cases at primary tumor (p = 0.6498), but not at metastasis (p = 0.0223), they expressed only one part on the TILs subpopulations (p = 0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p = 0.5034).
CONCLUSIONS: These findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.

Entities:  

Keywords:  Breast Cancer; Luminal; Microenvironment; T CD4+ FOXP3+; T CD8 + ; Tumor infiltrating lymphocytes (TILs)

Mesh:

Substances:

Year:  2021        PMID: 33691674      PMCID: PMC7944604          DOI: 10.1186/s12885-021-07960-z

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  31 in total

1.  Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

Authors:  M V Dieci; M C Mathieu; V Guarneri; P Conte; S Delaloge; F Andre; A Goubar
Journal:  Ann Oncol       Date:  2015-05-20       Impact factor: 32.976

2.  Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.

Authors:  Seho Park; Ja Seung Koo; Min Suk Kim; Hyung Seok Park; Jun Sang Lee; Jong Seok Lee; Seung Il Kim; Byeong-Woo Park
Journal:  Breast       Date:  2011-08-23       Impact factor: 4.380

3.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

4.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors:  Sherene Loi; Damien Drubay; Sylvia Adams; Giancarlo Pruneri; Prudence A Francis; Magali Lacroix-Triki; Heikki Joensuu; Maria Vittoria Dieci; Sunil Badve; Sandra Demaria; Robert Gray; Elisabetta Munzone; Jerome Lemonnier; Christos Sotiriou; Martine J Piccart; Pirkko-Liisa Kellokumpu-Lehtinen; Andrea Vingiani; Kathryn Gray; Fabrice Andre; Carsten Denkert; Roberto Salgado; Stefan Michiels
Journal:  J Clin Oncol       Date:  2019-01-16       Impact factor: 44.544

5.  Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Authors:  Ashley Cimino-Mathews; Xiaobu Ye; Alan Meeker; Pedram Argani; Leisha A Emens
Journal:  Hum Pathol       Date:  2013-05-21       Impact factor: 3.466

6.  Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer.

Authors:  Fatmagul Kusku Cabuk; Fatma Aktepe; Fatma Nilgun Kapucuoglu; Ipek Coban; Dauren Sarsenov; Vahit Ozmen
Journal:  Indian J Pathol Microbiol       Date:  2018 Apr-Jun       Impact factor: 0.740

Review 7.  Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Authors:  Sasha E Stanton; Sylvia Adams; Mary L Disis
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

8.  Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.

Authors:  Andrew E Teschendorff; Sergio Gomez; Alex Arenas; Dorraya El-Ashry; Marcus Schmidt; Mathias Gehrmann; Carlos Caldas
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

9.  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Authors:  Vassiliki Kotoula; Kyriakos Chatzopoulos; Sotiris Lakis; Zoi Alexopoulou; Eleni Timotheadou; Flora Zagouri; George Pentheroudakis; Helen Gogas; Eleni Galani; Ioannis Efstratiou; Thomas Zaramboukas; Angelos Koutras; Gerasimos Aravantinos; Epaminontas Samantas; Amanda Psyrri; Helen Kourea; Mattheos Bobos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  Oncotarget       Date:  2016-01-26

10.  Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

Authors:  Rin Ogiya; Naoki Niikura; Nobue Kumaki; Hiroyuki Yasojima; Tsutomu Iwasa; Chizuko Kanbayashi; Risa Oshitanai; Michiko Tsuneizumi; Ken-Ichi Watanabe; Akira Matsui; Tomomi Fujisawa; Shigehira Saji; Norikazu Masuda; Yutaka Tokuda; Hiroji Iwata
Journal:  Oncotarget       Date:  2017-10-27
View more
  1 in total

Review 1.  Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.

Authors:  Aadya Nayak; Neerada Meenakshi Warrier; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2022-07-25       Impact factor: 6.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.